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Abstract
Over the last decades, the treatment of schizophrenia has shifted fundamentally from a
focus on symptom reduction to a focus on recovery and improving aspects of functioning. In
this study, we examined the effect of transcranial direct current stimulation (tDCS) on social
cognitive and nonsocial neurocognitive functions, as well as on electroencephalogram
(EEG) measures, in individuals with schizophrenia. Thirty-seven individuals with schizo-
phrenia were administered one of three different tDCS conditions (cathodal, anodal, and
sham) per visit over the course of three visits, with approximately one week between each
visit. Order of conditions was randomized and counterbalanced across subjects. For the
active conditions, the electrode was placed over the left dorsolateral prefrontal cortex with
the reference electrode over right supraorbital cortex. Current intensity was 2 mA and was
maintained for two 20-minute sessions, with a one hour break between the sessions.
Assessments were conducted immediately following each session, in a counterbalanced
order of administration. No systematic effects were found across the social and nonsocial
cognitive domains, and no significant effects were detected on event-related potentials
(ERPs). The very small effect sizes, further validated by post-hoc power analyses (large
Critical Ns), demonstrated that these findings were not due to lack of statistical power.
Except for mild local discomfort, no significant side effects were reported. Findings demon-
strate the safety and ease of administration of this procedure, but suggest that a single dose
of tDCS over these areas does not yield a therapeutic effect on cognition in schizophrenia.
Trial registration: ClinicalTrials.gov NCT02539797.
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Introduction
Considerable evidence indicates that cognitive factors are key determinants of functional out-
come for schizophrenia [1–3]. These cognitive factors can be divided into neurocognition and
social cognition. Neurocognition refers to a wide range of performance abilities in domains
such as learning and memory, vigilance / attention, speed of processing, reasoning and prob-
lem solving, and working memory [4, 5]. Social cognition refers to cognitive abilities that are
needed to perceive, interpret, and process social information and include domains such as
emotion perception, social context processing, attributional bias, and theory of mind [6, 7].
Both neurocognitive and social cognitive deficits have been extensively documented in schizo-
phrenia literature and are considered a core feature of the illness [8–10].
In addition to the considerable efforts in recent years to stimulate the development of cog-
nition-enhancing drugs [11, 12], other approaches to enhance patients’ cognitive functions
have been explored. Neurostimulation has advantages over pharmacological therapy in reduc-
ing many potentially dangerous systemic side effects. Currently transcranial direct current
stimulation (tDCS) has been developed as non-invasive tool using neurostimulation to treat
epilepsy [13]. Unlike other non-invasive brain stimulation techniques, such as transcranial
electrical stimulation or transcranial magnetic stimulation, tDCS does not induce neuronal fir-
ing by suprathreshold neuronal membrane depolarization but rather modulates spontaneous
neuronal network activity [14]. In a review of 567 tDCS sessions administered over cortical
areas on a total of 102 healthy participants and patients, none requested the stimulation to be
terminated or needed any medical intervention during or after tDCS administration [15].
Despite the safety and tolerability of this procedure, findings regarding its potential clinical
benefits in schizophrenia have been mixed. Early studies of single tDCS administration in
schizophrenia reported positive effects [16–18]. For example, Brunelin et al. (2012) reported
preliminary data showing that bifocal stimulation (anodal over DLPFC and cathodal over
tempo-parietal cortex) improved scores on measures of auditory hallucinations and overall pos-
itive and negative symptoms in 2 patients with refractory schizophrenia. The clinical efficacy
appeared immediately after stimulation sessions and was maintained or continued to improve
during at least 3 months. The authors noted that no adverse events were reported, and that the
two patients only described a transient mild tingling or a slight itching sensation associated with
the onset of stimulation, thereby confirming the safety of this technique [16]. Additionally, Ver-
cammen et al. (2011) examined whether anodal tDCS to the left DLPFC would reverse probabi-
listic association learning deficits in 20 individuals with schizophrenia. The authors reported no
adverse effects following the procedure and demonstrated a beneficial effect of tDCS on perfor-
mance, as assessed by the weather prediction test, in a subsets of individuals [19].
Other studies, however, reported negative findings. For example, in two randomized, dou-
ble-blind, controlled trials, Fitzerald et al. (2014), examined the effects of unilateral and bilat-
eral tDCS (anodal stimulation to the prefrontal cortex and cathodal stimulation to the
temporoparietal junction) in patients with persistent hallucinations and negative symptoms of
schizophrenia. They reported that, despite the tolerability of the procedure, neither unilateral
nor bilateral tDCS resulted in a substantial change in either hallucinations or negative symp-
toms [20]. Mattai et al. (2011) investigated the tolerability aspects of tDCS in childhood-onset
schizophrenia. The investigators administered bilateral anodal DLPFC stimulation or bilateral
cathodal superior temporal gyrus (STG) stimulation to children between the ages 10–17.
While demonstrating the safety and tolerability of this procedure in a pediatric population, no
changes in cognitive measures in favor of any stimulation condition were observed [21].
The present study was an effort to evaluate the effect of single tDCS administration in
schizophrenia on a broad range of social cognitive, nonsocial neurocognitive, and EEG
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measures. We employed a commonly used montage in cognitive enhancement tDCS studies
over the course of three sessions, with approximately one week between each session: anodal
tDCS over left DLPFC (cathodal over right supraorbital), cathodal tDCS over left DLPFC
(anodal over right supraorbital), and sham stimulation. Using a reasonably well-powered
cross-over design, we sought to detect a differential effect of these types of stimulation on per-
formance-based tasks and brainwave activity that are mediated by frontal brain regions.
Material and methods
Participants
Participant recruitment and follow-up were conducted between May 2015 and July 2016. As
described in detail previously [15, 17], participants were recruited by placing ads and receiving
referrals from treating clinicians at outpatient clinics at the UCLA and the VA Greater Los
Angeles Healthcare System and through presentations in the community. All patients were
administered the Structured Clinical Interview for DSM-IV (SCID-P) [22]. All interviewers
were trained to administer the SCID by the Diagnostic Core of the Mental Illness Research,
Education, and Clinical Center (MIRECC) Treatment Unit, and were required to obtain a
Kappa of 0.75 for key psychotic and mood items before proceeding to interview participants
independently. Participants were included if they met the DSM-IV diagnostic criteria for
Schizophrenia or Schizoaffective Disorder [23], were between the ages of 18–55, were able to
understand spoken English sufficiently to comprehend testing procedures, and were under the
current ongoing care of a psychiatrist, psychologist, or other qualified mental health profes-
sional. Patients were excluded if they had an identifiable neurological condition, metal in the
cranium, intracardiac lines, cardiac pacemaker, medication pump, or increased intracranial
pressure, psychiatric inpatient hospitalization in the last three months, substantial changes in
their antipsychotic medications during the previous 6 weeks, IQ < 70 based on reading ability,
or met criteria for substance dependence in the last six months.
The present study included 38 individuals (one participant was lost to follow-up after miss-
ing several appointments and testing window; see Fig 1) with schizophrenia or schizoaffective
disorder (68% males), all receiving antipsychotic medications (93% atypical). Mean age was
42.7 (SD = 8.57; range = 23–55), mean participants’ education was 12.8 (SD = 2.11; range = 8–-
18), and mean paternal education was 13.6 (SD = 3.51; range = 3–20). Patients’ mean illness
chronicity was 20.1 years (SD = 9.54; range = 3–43). Mean symptom ratings on the Brief Psy-
chiatric Rating Scale (BPRS) was 42.1 (SD = 12.0; range = 25–77) and on the Scale for the
Assessment of Negative Symptoms (SANS) was 41.0 (SD = 16.0; range = 13–80). All partici-
pants gave written informed consent after receiving a full explanation of the research accord-
ing to procedures approved by the UCLA and the VA Greater Los Angeles Healthcare System
Institutional Review Boards. The approved protocol is included in supporting information
(see S1 Protocol). The trial was registered at www.ClinicalTrials.gov (NCT02539797). The
authors confirm that all ongoing and related trials for this intervention are registered.
Assessments
Symptom ratings were collected using the expanded BPRS [24] and the SANS [25]. Standard-
ized social cognitive and nonsocial cognitive assessments included a number of primary mea-
sures that have been used in schizophrenia research [7]. Participants also rated on a 5-point
Likert scale (ranging from none to severe; 0–4) common side effects that are typically reported
following tDCS administration [15, 17]. The measures administered are listed in Table 1 and
are described fully below.
tDCS in schizophrenia
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Social cognitive measures. Managing Emotions component of Mayer-Salovey-Caruso
Emotional Intelligence Test (MSCEIT) [26] consists of 141 items and 8 ability subtests, which
assess four components of emotional processing. In this study, only branches 1 and 4 were
administered, focusing on the Managing Emotions component. Emotion Identification
Test (EIT) from the Ekman Program is a test of identification of facial emotion based on
Fig 1. CONSORT flow chart.
https://doi.org/10.1371/journal.pone.0197023.g001
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photographs from the software developed by Ekman [27]. It includes 56 color photographs of
eight different individuals displaying facial expressions of six basic emotions (happy, sad,
angry, afraid, surprised, and disgusted). The Awareness of Social Inference Test (TASIT) [28]
consists of 16 videotaped scenes with two or three actors appearing in each scene. The scenes
involve two types of conversational exchanges, enacted as either a lie (a white lie or a sympa-
thetic one) or sarcasm. After each scene, participants answer questions (yes/no) about the
actors’ communicative intentions, such as whether the actors wanted the literal or nonliteral
meaning of their messages to be believed. The Empathic Accuracy Task (EAT) [29] assesses
the accuracy of empathic judgments using 12 video clips (six positive and six negative events),
in which individuals (referred to as “targets”) discuss a positive or negative autobiographical
event. As participants watch the clip, they use a 9-point scale to continuously rate how positive
or negative they believe the target was feeling at each moment.
Nonsocial neurocognitive measures. The neurocognitive assessment consisted of the
MATRICS Consensus Cognitive Battery (MCCB), which assesses seven separate cognitive sub-
domains, including one measure of social cognition, the managing emotions component of
the MSCEIT [4, 30, 31]. Given the diminishing tDCS effect over time [32], we included four
nonsocial neurocognitive tasks: speed of processing, working memory, verbal memory, and
reasoning/problem solving. Normed T scores were calculated for each cognitive subdomain,
as well as the cognitive composite score consisting of the average across the four subdomains.
EEG measures. EEG was acquired with a Neuroscan NuAmps amplifier (Compumedics
USA, El Paso, Texas) continuously throughout the session. Data were sampled at 1000 Hz
from DC to 100 Hz. Nineteen cap-mounted Ag-AgCl electrodes were positioned using a modi-
fied international 10–20 system placement scheme. Additionally, 2 electrodes were used to
measure vertical electro-oculogram (placed above and below the left eye) and used in eyeblink
correction [33]. All electrodes were referenced to the mastoids, unless otherwise noted.
Mismatch negativity (MMN) was measured using a passive attention auditory duration
deviant paradigm. Subjects were presented with binaural tones (1 kHz 85 dB sound pressure
level, with 10 ms rise/fall). Standard (90% probability; 50 ms duration) and duration-deviant
(10% probability; 100 ms duration) tones were presented in a fixed, pseudorandom order. Full
Table 1. Measure administered to assess the effect of stimulation.
Social Cognitive Measures
MSCEIT
EIT
TASIT
EAT
Nonsocial Cognitive Measures
MCCB
EEG Measures
MMN
P300
N170
MSCEIT: Mayer-Salovey-Caruso Emotional Intelligence Test; EIT: Emotion Identification Test; TASIT: The
Awareness of Social Inference Test; EAT: Emphatic Accuracy Task; MCCB: MATRICS Consensus Cognitive Battery;
EEG: Electroencephalogram; MMN: Mismatch Negativity; The order of assessments was fully counter-balanced
across subjects.
https://doi.org/10.1371/journal.pone.0197023.t001
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details regarding stimulus presentation and EEG recording and analysis are presented else-
where [34]. The mean amplitude between 135–205 ms of the deviant-standard difference wave
was calculated at electrode Fz.
Following MMN, P300 wave was measured using an active attention auditory oddball para-
digm. Subjects were presented with standard (88% probability; 1 kHz frequency; 100 ms dura-
tion) and target (12% probability; 1.5 kHz frequency; 100 ms duration) tones. They were
instructed to pay attention to the stimulus stream and press a button when they heard the
high-pitched tone (infrequent target stimulus) while disregarding the low-pitched tone (stan-
dard stimulus). The peak amplitude between 300–600 ms at electrode Pz was extracted and
analyzed for oddball stimuli.
The N170 wave was based on a modified procedure we previously developed, where details
of recording and analyses are provided [35, 36]. Briefly, in separate blocks, participants viewed
either faces or buildings. For faces [37], participants had to determine the emotion displayed
(afraid, angry, ashamed, happy, sad, or surprised); for buildings, they had to determine if they
were 1 or 2 stories tall. The EEG was re-referenced to the grand average of the 19 electrodes.
The mean amplitude between 140–180 ms was averaged across electrodes P7 and P8 for faces
and buildings.
Electrical stimulation
As described in detail previously [17], the tDCS was delivered by an Activa Dose II Iontopho-
resis Delivery Unit (IOMED, Inc), using a pair of saline-soaked sponge electrodes held in
place by elastic bands. The 5 x 7 cm active electrode (anodal or cathodal) was placed over the
left DLPFC (F3 EEG site), with the 5 x7 cm reference electrode over the right supraorbital cor-
tex (Fp2 EEG site), in accordance with the 10/20 International System [38]. The current inten-
sity was set at 2 mA with a current density of 0.057 mA/cm2 at the skin at each electrode. A
variable resistor was included in series with each active electrode, which allowed for continu-
ous monitoring of current delivered and ensured that equivalent intensity balanced at 1 mA
per active electrode. In the sham condition, the current was turned on for 30 seconds and then
ramped down to 0 mA. In this way, the participants experience the same initial sensation of
mild tingling, thus preserving the sham manipulation [15]. The research assistants administer-
ing the procedure were not blinded to the stimulation condition.
Procedures
We used a cross-over counter-balanced design. Participants came for three visits, approxi-
mately one week apart. The duration of the first visit was approximately 4 hours, whereas the
second and third visits each took approximately 2.5 hours. At each visit they were adminis-
tered one of three randomly assigned tDCS conditions: anodal over left DLPFC (cathodal over
right supraorbital), cathodal over left DLPFC (anodal over right supraorbital), or sham. (Dur-
ing the first visit, they also completed the diagnostic interviews and questionnaires.) At each
visit, participants received two 20-minute stimulation sessions, with approximately 100 min-
utes between the sessions, in which one stimulation was followed by cognitive testing and the
other was followed by EEG. To address potential practice effects, the design of the study was
fully counterbalanced, making practice effects orthogonal to the condition effects and thus
avoiding confounds with the experimental conditions. Specifically, the order of assessments
(cognitive and EEG) was counter-balanced across subjects. Further, within the cognitive
assessments, we counter-balanced social cognitive and neurocognitive measures across
subjects.
tDCS in schizophrenia
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Statistical analyses
Generalized Linear Mixed Models (GLMM) analyses were conducted, using IBM SPSS Statis-
tics, Version 25, to examine the effects of tDCS on patients’ performance on social cognitive,
neurocognitive, and EEG measures. For all non-significant findings, the results of post-hoc
power analyses are presented as the critical N, that is, the sample size required for 80% power
to detect an effect of this size. In cases where the estimated non-centrality parameter is negative
(i.e., the observed differences between means are actually smaller than would be expected by
chance), the critical N is reported as NA and observed power as 0, as the pattern of results is
more consistent with the null hypothesis than any possible alternative; and regardless of how
large the sample is, this pattern of results will never yield a significant result. The dataset is
available in supporting information (see S1 Dataset).
Results
GLMM analyses were conducted to examine the effects of tDCS on patients’ performance.
tDCS condition (anodal, cathodal, and sham) was modeled as a within-subject effect, and a
random effect for patient effects was included to account for individual differences between
participants. As can be seen in Table 2, none of the social cognitive measures were significantly
affected by the stimulation condition. Similarly, tDCS condition had no significant effect on
nonsocial cognition, or the cognitive composite. The only measure significantly affected by
stimulation was working memory, showing higher performance in the sham condition than in
the anodal and cathodal conditions. Finally, none of the EEG measures demonstrated a signifi-
cant effect of tDCS (see Table 2).
GLMM analyses were also conducted to examine the common side effects of tDCS. As can
be seen in Table 3, participants reported significantly more itching, pain, burning, and heat
sensations following the anodal and cathodal stimulations, as compared with sham. However,
none of the side effects presented substantial discomfort for the participants, as most of the
symptoms were rated either as none or mild (below 1) on the scale, and none requested to dis-
continue the procedure.
Discussion
In this study, we examined the effect of single tDCS administration in schizophrenia on a
broad range of social cognitive, nonsocial neurocognitive, and ERP measures. Employing a
commonly used montage in cognitive enhancement tDCS studies in a cross-over design, we
found that none of the social cognitive measures nor any of the EEG measures were signifi-
cantly affected by the stimulation condition. Similarly, tDCS condition had no significant
effect on nonsocial neurocognition, including the cognitive composite score. The only mea-
sure significantly affected by stimulation was working memory, with both anodal and cathodal
stimulations adversely affecting performance. The very small effect sizes, further validated by
post-hoc power analyses (large Critical Ns), demonstrated that these findings were not due to
lack of statistical power.
The present findings, combined with the inconsistency of therapeutic effects reported in
studies of single tDCS administration, underscore the need to examine alternative tDCS mon-
tages. Along these lines, recent studies have examined the effects of tDCS at different intensi-
ties and/or across multiple sessions [39–42]. For example, Hoy et al. (2014) examined the
effects of anodal left dorsolateral prefrontal tDCS at different intensities (1mA, 2mA, sham)
and measured performance across three time points post-stimulation (0, 20 and 40 min). They
found a significant improvement in performance over time following 2 mA stimulation only,
demonstrating the importance of dose of stimulation [42]. Similarly, Brunelin et al. (2012)
tDCS in schizophrenia
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administered active 2 mA tDCS to individuals with schizophrenia for 20 minutes twice a day
on 5 consecutive weekdays. They reported a robust reduction in auditory verbal hallucina-
tions, with the beneficial effect lasting for up to 3 months [40]. Smith et al. (2015) conducted a
randomized double-blind, sham-controlled study of the effects of 5 sessions of tDCS on cogni-
tive and psychiatric symptoms in individuals with schizophrenia or schizoaffective disorder.
They reported significant improvements after the fifth tDCS session in MCCB Composite
Table 2. Performance data on measures of social cognition, neurocognition, and EEG (N = 37).
Anodal Cathodal Sham F p f2 Observed Critical
M±SE M±SE M±SE Power N
Social Cognition
MSCEIT 36.4±2.06 37.7±2.05 37.1±2.05 0.282 0.755 0.008 0 NA
EIT 44.9±1.39 43.9±1.37 44.9±1.39 0.475 0.624 0.013 0 NA
TASIT 22.1±0.71 22.4±0.70 22.5±0.70 0.457 0.635 0.013 0 NA
EAT 0.49±0.04 0.49±0.04 0.49±0.04 0.002 0.998 <0.001 0 NA
Neurocognition
MCCB CCS 45.0±1.65 45.2±1.65 45.8.6±1.64 0.462 0.632 0.013 0 NA
MCCB SP 44.7±2.19 45.4±2.18 45.1±2.18 0.148 0.862 0.004 0 NA
MCCB WM 38.2±2.19 38.0±2.18 40.9±2.18 3.754 0.028 0.110
MCCB VM 45.7±2.19 44.3±2.18 44.7±2.18 0.417 0.660 0.012 0 NA
MCCB RPS 51.4±1.68 53.1±1.67 52.5±1.67 0.683 0.509 0.020 0 NA
EEG
MMN FZ -3.44±0.30 -3.64±0.29 -3.35±0.29 0.529 0.592 0.015 0 NA
P300 Peak
Latency 472.6±16.1 440.5±15.5 422.8±15.7 3.076 0.053 0.090 0.61 54
P300 Peak
Amplitude 7.22±0.98 7.03±0.96 7.73±0.97 0.494 0.613 0.014 0 NA
N170 Emotion -2.52±0.40 -3.26±0.39 -2.71±0.39 1.935 0.154 0.057 0.29 135
N170 Building 0.56±0.29 0.62±0.28 0.56±0.28 0.027 0.974 <0.001 0 NA
MSCEIT: Mayer-Salovey-Caruso Emotional Intelligence Test; EIT: Emotion Identification Test; TASIT: The Awareness of Social Inference Test; EAT: Emphatic
Accuracy Task; MCCB: MATRICS Consensus Cognitive Battery; CCS: Cognitive Composite Score; SP: Speed of Processing; WM: Working Memory; VM: Verbal
Memory; RPS: Reasoning and Problem Solving; EEG: Electroencephalogram; MMN: Mismatch Negativity; M±SE: Mean±Standard Error; Critical N is the sample size
required for 80% power to detect the reported effect; In cases where the estimated non-centrality parameter is negative, the critical N is reported as NA and observed
power as < 0.05.
https://doi.org/10.1371/journal.pone.0197023.t002
Table 3. Side effects following tDCS administration (N = 37).
Anodal Cathodal Sham F p
M±SE M±SE M±SE
Itching 1.27±0.19 1.41±0.18 0.50±0.18 8.801 <0.001
Pain 0.26±0.10 0.44±0.10 0.13±0.10 4.647 0.013
Burning 0.90±0.18 1.16±0.17 0.44±0.17 7.418 0.001
Heat 0.73±0.12 0.41±0.12 0.29±0.12 6.860 0.002
Pinching 0.32±0.12 0.39±0.12 0.19±0.12 0.836 0.438
Iron Taste 0.12±0.06 0.08±0.06 0.06±0.06 0.293 0.747
Fatigue 0.58±0.15 0.61±0.15 0.36±0.15 1.108 0.336
M±SE: Mean±Standard Error
https://doi.org/10.1371/journal.pone.0197023.t003
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score and on the MCCB Working Memory and Attention-Vigilance domain scores, with large
effect sizes [41]. These latter two studies demonstrate the potentially cumulative effect of mul-
tiple tDCS session.
Another approach that should be incorporated in future studies involves online (task-con-
current) tDCS. In this montage, participants engage in cognitive training while concurrently
receiving active tDCS. Recent studies suggest that this paradigm may be particularly effective
for enhancing certain cognitive functions [43–45]. Au et al. (2016), for example, administered 7
days of working memory training concurrent with active either active (left or right DLPFC) or
sham tDCS to a sample of healthy individuals. They found that active tDCS enhanced training
performance, which was preserved several months after training completion [43]. Similarly,
Ruff et al. (2017) examined the effect on healthy adults of three consecutive training sessions
concurrent with tDCS on both spatial and verbal working memory. They compared active
tDCS over DLPFC in a task-congruent (spatial-right, verbal-left), task-incongruent (spatial-left,
verbal-right), and sham stimulation in regards to the efficacy of WM training and found a
steeper learning curve when WM training was combined with task-congruent tDCS, with
effects lasting for up to nine months and transferring to respective untrained tasks [44]. Finally,
Oldrati et al. (2018) compared the effects of online vs. offline tDCS on enhancing training on a
visuospatial task. They administered anodal tDCS of DLPFC either before or during training to
a sample of healthy volunteers and found that, compared with the sham condition, the largest
improvement occurred in the online tDCS condition [45]. These studies thus underscore the
facilitative and long-lasting effects of tDCS when applied concurrently with cognitive training.
Considerable efforts have been made to find ways to enhance cognition in schizophrenia,
mostly focusing on psychopharmacological approaches [4, 11, 46]. In recent years, neurosti-
mulation has been developed as a non-invasive tool for cognitive enhancement [19, 21, 47, 48].
Neurostimulation has some advantages over psychopharmacology in that it is relatively safe
with few side effects [49]. The tDCS procedure was well-tolerated in our study, with most com-
mon side effects being itching, pain, burning, and heat sensations, which followed both the
anodal and cathodal stimulations. Importantly, most of the side effects were rated as mild or
below, and none of the participants requested to discontinue the procedure. These findings are
consistent with numerous reports [15, 20, 21], clearly establishing the safety and tolerability of
single tDCS administration.
A number of limitations of the current study should be noted. In an effort to blind partici-
pants to the type of stimulation, we created a sham condition in which the current was turned
on for 30 seconds and then ramped down to 0 mA. In this way, participants experienced the
same initial sensation of mild tingling that is experienced during anodal and cathodal stimula-
tions. Nonetheless, when comparing self-reported measures of side effects across the stimula-
tion conditions, participants reported significantly more itching, pain, burning, and heat
sensations following the anodal and cathodal stimulations, as compared with sham. Thus,
although these side effects were very mild, findings suggest that actual tDCS conditions are
experienced differently than sham. Additionally, the research assistants administering the pro-
cedure were not blinded to the stimulation condition, which could have also potentially influ-
enced the sensations reported by the participants. Importantly, these findings are limited to
effects of single tDCS administration, as assessed by changes from baseline to immediately
post-stimulation. It could have been informative to conduct multiple tDCS sessions, while ana-
lyzing potential effects on a session to session basis. Unfortunately, practice effects, which are
inherent in most performance-based measures, limit the applicability of these approaches in
clinical trials of this type.
In summary, although these findings support the safety and tolerability of single tDCS
administration, using a reasonably well-powered cross-over design, we failed to detect a
tDCS in schizophrenia
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differential tDCS effect of stimulation condition on neurocognitive and social cognitive perfor-
mance-based tasks, as well as on EEG measures. These findings thus add to the growing body
of evidence suggesting the potentially suboptimal dose of the single tDCS administration and
point to the need for basic dose-finding studies in tDCS, as there would be for a new pharma-
cological intervention. Given its safety, tolerability, portability, relatively cheap cost, and ease
of administration, once therapeutic dose is established, tDCS could potentially become a valu-
able therapeutic tool in the treatment of neurocognitive and social cognitive deficits in
schizophrenia.
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